Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. - Wikidata - awgldk - TriplyDB

Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

http://www.wikidata.org/entity/Q40656134

about

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.Multifaceted and personalized therapy of advanced prostate cancer.Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Emerging Variants of Castration-Resistant Prostate Cancer.Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

P2860

Q31137270-74149ACB-0822-446D-9CBF-703855780C18 Q35925835-BCFC8BF7-9543-45F1-8FE0-E1E0FCD10DF1 Q38634711-C6678EB2-8B81-4F1A-9139-CC7FE36F789B Q38722718-FA88552E-1395-4447-9B2C-B81258B4CBE2 Q38780436-6F14BF5C-2F82-4E18-B1B2-861EFED92233 Q38868832-686D465B-3238-4709-B14F-7641B5C3216D Q38966736-DE46EBA3-924A-495B-80F2-FA4A3AB20D3F Q39210257-FBC05E64-C008-4478-9C14-7E15E207BBA4 Q47140347-573E5459-6512-48C4-B4CD-DB73283E5E38 Q51033341-793E27DC-FF3E-41E5-9A02-5A128D8137F3 Q53682879-CCC28E46-318B-4FD7-8F6D-9F59A49E5B21

P2860

Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

http://www.wikidata.org/entity/Q40656134

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cyclin D1 Loss Distinguishes P ...... ost Prostatic Adenocarcinomas.

@en

type

label

Cyclin D1 Loss Distinguishes P ...... ost Prostatic Adenocarcinomas.

@en

prefLabel

Cyclin D1 Loss Distinguishes P ...... ost Prostatic Adenocarcinomas.

@en

P1433

Q40656134-A6BCD183-2462-4327-A5D2-22CA6B083A5F

P1476

Q40656134-81300575-958B-4CCC-B4A7-3F134A112F51

P2093

Q40656134-4BD6EE6D-A099-4187-B0FB-B76C3D22C81C

Q40656134-51A38BBC-0976-4FED-9D3D-27DECC5D592C

Q40656134-5D7B5270-B8A3-451C-B9BE-416CF9CA9C9F

Q40656134-5DF45B57-6820-4747-9B18-BBA750E09B83

Q40656134-6C047EDC-FF62-4B81-AFB5-11E32AF8BCF1

Q40656134-8554B34D-7C49-4440-B934-BE84F822181D

Q40656134-8B708CF1-DE81-4F02-93EF-1FE559DC2272

Q40656134-A0569B8A-3972-459E-B67F-F22CE56209FB

Q40656134-A36E8D2B-1BFE-462E-AE4E-F59E631D5099

Q40656134-A96B1BBC-FCA6-45F8-9C57-885C9D799443

P2860

Q40656134-04359029-D3B7-4741-9DDE-F8EBB322BF99

Q40656134-0B63F521-67BF-4AB7-8172-9F79E0B715E0

Q40656134-12048707-005C-4D99-ACC9-3396F727FC2B

Q40656134-13A79E71-0883-4AF9-AF74-BFAAC8387069

Q40656134-1AA41C21-60B3-4ED5-8068-C82D45949C45

Q40656134-1BA88B32-461E-4C2D-ABF0-87A023E01C29

Q40656134-23E4F4AA-ED4C-4AE1-92D3-423267DCEAC5

Q40656134-288E36AA-38DC-4E7E-9838-8F04074394CF

Q40656134-56F76F79-C6D6-4969-993F-0C8933C55FD4

Q40656134-5C200FE7-4F3F-4E47-9821-06BED882D998

P304

Q40656134-7C1CB256-E67D-469E-9DF9-AACB39363222

P31

Q40656134-58E301B0-F247-45CB-9E06-9A64EF99BF00

P356

Q40656134-3FD27043-C452-4432-BF49-44F9C94EAD7D

P407

Q40656134-AD7A3EDF-E33E-4D41-B0E2-42DBBB9AD943

P433

Q40656134-5CEA2FDE-4140-49ED-B5C7-06E66062C693

P478

Q40656134-83857E24-3C7D-4D7B-A6B1-AB93F91A534E

P50

Q40656134-05A607A9-D750-4FD0-86BF-55FA4149A3D4

Q40656134-6B0198D5-ED83-4469-A846-7E22D97CC90A

Q40656134-951527E8-A9AE-4606-9096-A912BDA23C01

P577

Q40656134-F217D437-DA1F-4D0C-ACE4-92FBB14DA0FD

P698

Q40656134-898F12DD-8EDC-4518-9A47-35AB087F4801

P921

Q40656134-61846386-055F-423A-89A1-7535DD6F7605

P932

Q40656134-C87184AC-9A90-4F98-9E96-9755A5A4C65B

P356

1078-0432.CCR-15-0744

P1433

Clinical Cancer Research

P1476

Cyclin D1 Loss Distinguishes P ...... ost Prostatic Adenocarcinomas.

@en

P2093

Angelo M De Marzo

http://www.w3.org/2001/XMLSchema#string

Carlos L Morais

http://www.w3.org/2001/XMLSchema#string

George J Netto

http://www.w3.org/2001/XMLSchema#string

Harrison Tsai

http://www.w3.org/2001/XMLSchema#string

Hsueh-Li Tan

http://www.w3.org/2001/XMLSchema#string

Jessica Hicks

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Jun Luo

http://www.w3.org/2001/XMLSchema#string

Mohammed Alshalalfa

http://www.w3.org/2001/XMLSchema#string

Nilesh Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target

Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

The mutational landscape of lethal castration-resistant prostate cancer

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb.

P304

5619-5629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0744

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Edward M Schaeffer

P577

2015-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26246306

http://www.w3.org/2001/XMLSchema#string

P921

P932

4681606

http://www.w3.org/2001/XMLSchema#string